A new drug, Pemafibrate, currently in a phase 3 clinical trial in Japan, may significantly improve lipid profiles and insulin resistance in patients with type 2 diabetes and hypertriglyceridemia. The results follow those of several large-scale clinical trials which show that treatment with drugs of the fibrate class can decrease triglyceride levels and increase high-density lipoprotein (HDL) cholesterol levels, which can result in reduction of atherosclerotic cardiovascular disease risk in patients with type 2. Read more